These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30481388)

  • 21. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.
    Pelaia C; Calabrese C; Terracciano R; de Blasio F; Vatrella A; Pelaia G
    Ther Adv Respir Dis; 2018; 12():1753466618810192. PubMed ID: 30400762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
    Esquivel A; Busse WW; Calatroni A; Togias AG; Grindle KG; Bochkov YA; Gruchalla RS; Kattan M; Kercsmar CM; Khurana Hershey G; Kim H; Lebeau P; Liu AH; Szefler SJ; Teach SJ; West JB; Wildfire J; Pongracic JA; Gern JE
    Am J Respir Crit Care Med; 2017 Oct; 196(8):985-992. PubMed ID: 28608756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis.
    Evans MO; Morris MJ; Coop CA; Evans SE
    Ann Allergy Asthma Immunol; 2015 Sep; 115(3):250-1. PubMed ID: 26162570
    [No Abstract]   [Full Text] [Related]  

  • 24. 'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.
    Folqué MM; Lozano J; Riggioni C; Piquer M; Álvaro M; Machinena A; Giner MT; Domínguez O; Jiménez-Feijoo RM; Dias da Costa M; Plaza AM
    Allergol Immunopathol (Madr); 2019; 47(4):336-341. PubMed ID: 30509559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab.
    Rams A; Żółciński M; Zastrzeżyńska W; Polański S; Serafin A; Wilańska J; Musiał J; Bazan-Socha S
    J Asthma; 2018 Dec; 55(12):1384-1386. PubMed ID: 29300536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
    Carrier C; Demoly P; Caimmi D
    Rev Mal Respir; 2019 Feb; 36(2):191-196. PubMed ID: 30396780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
    Zhou H; Lu Y; Wu B; Che D
    J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
    [No Abstract]   [Full Text] [Related]  

  • 29. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous sarcoidosis in a patient with severe asthma treated with omalizumab.
    Yung S; Han D; Lee JK
    Can Respir J; 2015; 22(6):315-6. PubMed ID: 26401982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
    Lieberman PL; Umetsu DT; Carrigan GJ; Rahmaoui A
    J Allergy Clin Immunol; 2016 Sep; 138(3):913-915.e2. PubMed ID: 27236498
    [No Abstract]   [Full Text] [Related]  

  • 32. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to omalizumab in patients with severe allergic asthma: A real-life study.
    Zierau L; Walsted ES; Thomsen SF; Backer V
    Respir Med; 2017 Oct; 131():109-113. PubMed ID: 28947015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab].
    Romand P; Kelkel E; Saint-Raymond C; Glas N; Caillaud D; Devouassoux G
    Rev Mal Respir; 2016 May; 33(5):397-400. PubMed ID: 26346416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Th1-related disease development during omalizumab treatment: Two cases with severe asthma.
    Hayashi H; Fukutomi Y; Mitsui C; Watai K; Tomita Y; Kamide Y; Sekiya K; Tsuburai T; Horita A; Saito I; Hasegawa Y; Taniguchi M
    Allergol Int; 2018 Jul; 67(3):405-407. PubMed ID: 29191372
    [No Abstract]   [Full Text] [Related]  

  • 36. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effectiveness of omalizumab in the control of severe uncontrolled asthma in Latin America. An exploratory systematic review and meta-analysis].
    Miranda P
    Rev Alerg Mex; 2020; 67(1):19-24. PubMed ID: 32447864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
    Tortajada-Girbés M; Bousquet R; Bosque M; Carrera Martínez JJ; Ibáñez MD; Moreira A; Nieto A; Plaza AM; Rivas C; Requena G; Sánchez-Solis M; Tabar A; Torres-Borrego J; Zapatero L
    Expert Rev Respir Med; 2018 Sep; 12(9):745-754. PubMed ID: 30141696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience.
    Chipps BE; Lanier B; Milgrom H; Deschildre A; Hedlin G; Szefler SJ; Kattan M; Kianifard F; Ortiz B; Haselkorn T; Iqbal A; Rosén K; Trzaskoma B; Busse WW
    J Allergy Clin Immunol; 2017 May; 139(5):1431-1444. PubMed ID: 28477722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.